標(biāo)題：Research Grade Palivizumab 帕利珠單抗,AntibodySystem Laboratories

鏈接：https://www.antibodysystem.com/product/6108.html

名稱：Research Grade Palivizumab 帕利珠單抗

別名：Palivizumab ，帕利珠單抗，抗體，MEDI-493

CAS: 188039-54-5

貨號：DVV02801

適用物種：HRSV-A

寄主物種：Humanized

形式：Liquid

純度：>95%

克隆性：Monoclonal

同種型：IgG1, kappa

應(yīng)用：Research Grade Biosimilar

UniProt：P03420

靶點(diǎn)：F, Fusion glycoprotein F0, Fusion glycoprotein F2, p27, Intervening segment, Pep27, Peptide 27, Fusion glycoprotein F1

用途范圍：僅用于科研

儲存：Use a manual defrost freezer and avoid repeated freeze-thaw cycles.Store at +4°C short term (1-2 weeks).Store at -20 °C 12 months. Store at -80°C long term.

產(chǎn)品購買聯(lián)系方式：027-65279366 /18162686757

郵箱：biolab-reagents@atagenix.com

QQ：2663991332

 

參考文獻(xiàn)：

Palivizumab for preventing severe respiratory syncytial virus (RSV) infection in children. PMID: 34783356

Palivizumab. PMID: 10473022

Palivizumab prophylaxis in preterm infants. PMID: 28219614

Palivizumab: an overview. PMID: 10707171

Safety of Nirsevimab for RSV in Infants with Heart or Lung Disease or Prematurity. PMID: 35235733

Palivizumab: where to from here? PMID: 19063700

Nirsevimab for Prevention of RSV in Term and Late-Preterm Infants. PMID: 37018470

Palivizumab Use in the NICU: 1999-2020. PMID: 35730329

Palivizumab Prophylaxis in Infants and Young Children at Increased Risk of Hospitalization for Respiratory Syncytial Virus Infection. PMID: 37357729

RSV Prevention in All Infants: Which Is the Most Preferable Strategy? PMID: 35572550

Guidance for palivizumab prophylaxis and implications for compliance. PMID: 34547834

Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis. PMID: 20166098

Efficacy of nirsevimab against respiratory syncytial virus lower respiratory tract infections in preterm and term infants, and pharmacokinetic extrapolation to infants with congenital heart disease and chronic lung disease: a pooled analysis of randomised controlled trials. PMID: 36634694

Variation in clinical practice guidelines for use of palivizumab in preventing severe respiratory syncytial viral (RSV) disease in high-risk infants. PMID: 36748923

Expert consensus on palivizumab use for respiratory syncytial virus in developed countries. PMID: 31060948

Adherence and outcomes: a systematic review of palivizumab utilization. PMID: 29130355

Respiratory Syncytial Virus Bronchiolitis in Children. PMID: 28084708

Respiratory Syncytial Virus Bronchiolitis: Rapid Evidence Review. PMID: 37440737

Palivizumab prophylaxis in 'late preterm' newborns. PMID: 20695756

Bronchiolitis: an update on management and prophylaxis. PMID: 31059347

Is palivizumab effective as a prophylaxis of respiratory syncytial virus infections in cystic fibrosis patients? A meta-analysis. PMID: 24231153

Neutralizing epitopes of RSV and palivizumab resistance in Japan. PMID: 28867684

Palivizumab and Long-term Outcomes in Cystic Fibrosis. PMID: 31239289

Palivizumab in the prevention of respiratory syncytial virus disease. PMID: 12387675

Palivizumab in the prophylaxis of respiratory syncytial virus infection. PMID: 16207163

Updated cost-effectiveness analysis of palivizumab (Synagis) for the prophylaxis of respiratory syncytial virus in infant populations in the UK. PMID: 33107769

Palivizumab's real-world effectiveness: a population-based study in Ontario, Canada, 1993-2017. PMID: 32859612

Palivizumab prophylaxis in preterm infants and subsequent wheezing/asthma: 10-year follow-up study. PMID: 38116923

New strategies for the prevention of respiratory syncytial virus (RSV). PMID: 36174288

RSV through the COVID-19 pandemic: Burden, shifting epidemiology, and implications for the future. PMID: 36811330

Palivizumab reimbursement criteria and neonatal RSV hospitalisation: a regional retrospective review. PMID: 33748434

Revised recommendations concerning palivizumab prophylaxis for respiratory syncytial virus (RSV). PMID: 26670908

Consensus conference on the appropriateness of palivizumab prophylaxis in respiratory syncytial virus disease. PMID: 27618642

Palivizumab in congenital heart disease: should international guidelines be revised? PMID: 17961086

Administration of Palivizumab in the NICU. PMID: 27164941

Improving the prescribing of palivizumab. PMID: 29863814

The potential impact of palivizumab on pediatric airway reconstruction. PMID: 16360816

Systematic Review of the Safety and Efficacy of Palivizumab among Infants and Young Children with Cystic Fibrosis. PMID: 28423192

Treatment of respiratory syncytial virus with palivizumab: a systematic review. PMID: 21080142

Utilization and efficacy of palivizumab for children with Down syndrome. PMID: 31961027